{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/RLMD",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is RELMADA THERAPEUTICS, INC., listed on NASDAQ under ticker RLMD, with ISIN US75955J4022 and LEI 549300217EASRZ9JSF81. Its security type is Corporate, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States — Nevada. Its segment is not on the record. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 44 filings in the twelve months to 2026-11-08, across 29 filing days. The median gap between filing days is 8.0 days, against a NASDAQ median of 6.0 days and a sector median of 6.0 days. The latest filing is dated 2026-09-11 and is of type directors_dealings. Days from the latest filing to the record date are 58, against a NASDAQ median of 5.0 days and a sector median of 4.0 days. The NASDAQ median filings count is 52 and the sector median is 63.0.\n\n## Auditor\n\nThe auditor of record is CBIZ CPAs P.C., located in Houston, Texas. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe record names four research houses on the issuer's investor-relations page: Jefferies, Leerink, Piper Sandler and H.C. Wainwright & Co., a count of 4.\n\n## Open research\n\nNo openly published research notes were found for the issuer.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for the issuer. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n10 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest (identity.isin)\n- https://data.sec.gov/submissions/CIK0001553643.json (identity.jurisdiction)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/RLMD (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/ea0273255-10k_relmada.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.relmada.com/investors/stock-information/ (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/RLMD (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/ea0273255-10k_relmada.htm",
    "state": "sourced",
    "value": "CBIZ\nCPAs P.C."
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/ea0273255-10k_relmada.htm",
    "state": "sourced",
    "value": "199"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/ea0273255-10k_relmada.htm",
    "state": "sourced",
    "value": "Houston, Texas"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/RLMD",
  "coverage": {
   "count": 4,
   "houses": [
    {
     "analyst": "Farzin Haque, Ph.D.",
     "house": "Jefferies",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.relmada.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Andrew Berens, M.D.",
     "house": "Leerink",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.relmada.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Kelsey Goodwin",
     "house": "Piper Sandler",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.relmada.com/investors/stock-information/",
     "state": "sourced"
    },
    {
     "analyst": "Andres Maldonado, Ph.D.",
     "house": "H.C. Wainwright & Co.",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.relmada.com/investors/stock-information/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.relmada.com/investors/stock-information/",
     "result": "read: 4 of 8 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "agm_egm": 4,
    "corporate_news": 3,
    "director_change": 1,
    "directors_dealings": 9,
    "prospectus": 4,
    "regulatory_filing": 15,
    "results": 8
   },
   "cadence_median_gap_days": 8,
   "filing_days": 29,
   "filings": 44,
   "latency_days": 58,
   "latest": [
    {
     "category": "4",
     "date": "2026-09-11",
     "source": "https://www.sec.gov/Archives/edgar/data/1553643/000121390026098970/xslF345X06/ownership.xml",
     "title": "4 — OWNERSHIP DOCUMENT",
     "type": "directors_dealings"
    },
    {
     "category": "4",
     "date": "2026-09-11",
     "source": "https://www.sec.gov/Archives/edgar/data/1553643/000121390026098969/xslF345X06/ownership.xml",
     "title": "4",
     "type": "directors_dealings"
    },
    {
     "category": "8-K",
     "date": "2026-09-08",
     "source": "https://www.sec.gov/Archives/edgar/data/1553643/000121390026097851/ea0304768-8k_relmada.htm",
     "title": "8-K — CURRENT REPORT (items 8.01)",
     "type": "corporate_news"
    },
    {
     "category": "SCHEDULE 13G/A",
     "date": "2026-08-14",
     "source": "https://www.sec.gov/Archives/edgar/data/1553643/000205070926000025/xslSCHEDULE_13G_X02/primary_doc.xml",
     "title": "SCHEDULE 13G/A",
     "type": "regulatory_filing"
    },
    {
     "category": "8-K",
     "date": "2026-08-06",
     "source": "https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/ea0300993-8k_relmada.htm",
     "title": "8-K — CURRENT REPORT (items 2.02,7.01,9.01)",
     "type": "results"
    }
   ],
   "latest_filing_date": "2026-09-11",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/RLMD",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (ISINs mapped to the LEI)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest",
    "state": "sourced",
    "value": "US75955J4022"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001553643.json",
    "state": "sourced",
    "value": "United States — Nevada"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-08",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN US75955J4022)",
    "state": "sourced",
    "value": "549300217EASRZ9JSF81"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001553643.json",
    "state": "sourced",
    "value": "RELMADA THERAPEUTICS, INC."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001553643.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001553643.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "RLMD"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:582ae1a7655ac60bcffb2a2bd781a1a3287e2ab042fddc8f775ff86b1d21b721",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/RLMD",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:582ae1a7655ac60bcffb2a2bd781a1a3287e2ab042fddc8f775ff86b1d21b721",
 "path": "/us/NASDAQ/RLMD",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is RELMADA THERAPEUTICS, INC., listed on NASDAQ under ticker RLMD, with ISIN US75955J4022 and LEI 549300217EASRZ9JSF81. Its security type is Corporate, its sector is 2834 Pharmaceutical Preparations, and its jurisdiction is United States — Nevada. Its segment is not on the record. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 44 filings in the twelve months to 2026-11-08, across 29 filing days. The median gap between filing days is 8.0 days, against a NASDAQ median of 6.0 days and a sector median of 6.0 days. The latest filing is dated 2026-09-11 and is of type directors_dealings. Days from the latest filing to the record date are 58, against a NASDAQ median of 5.0 days and a sector median of 4.0 days. The NASDAQ median filings count is 52 and the sector median is 63.0.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is CBIZ CPAs P.C., located in Houston, Texas. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The record names four research houses on the issuer's investor-relations page: Jefferies, Leerink, Piper Sandler and H.C. Wainwright & Co., a count of 4.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found for the issuer.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for the issuer. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "10 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001553643.json"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/RLMD"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1553643/000121390026031862/ea0273255-10k_relmada.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.relmada.com/investors/stock-information/"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/RLMD"
  }
 ],
 "title": "RELMADA THERAPEUTICS, INC. (RLMD) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}